» Authors » Regis Lassalle

Regis Lassalle

Explore the profile of Regis Lassalle including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 83
Citations 1063
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Pajouheshnia R, Gini R, Gutierrez L, Swertz M, Hyde E, Sturkenboom M, et al.
Pharmacoepidemiol Drug Saf . 2024 Aug; 33(8):e5871. PMID: 39145406
Purpose: Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies (MINERVA), a European Medicines Agency-funded project (EUPAS39322), defined a set of metadata to describe real-world data sources (RWDSs) and...
2.
Gini R, Pajouheshnia R, Gutierrez L, Swertz M, Hyde E, Sturkenboom M, et al.
Pharmacoepidemiol Drug Saf . 2024 Aug; 33(8):e5884. PMID: 39145403
No abstract available.
3.
Thurin N, Grelaud A, Grolleau A, Bernard M, Bignon E, Blin P, et al.
Pharmacoepidemiol Drug Saf . 2024 Mar; 33(4):e5781. PMID: 38527971
Purpose: This paper aims to introduce an algorithm designed to identify Venous Thromboembolism (VTE) in the French National Healthcare Database (SNDS) and to estimate its positive predictive value. Methods: A...
4.
Hurley E, Geisler B, Lupattelli A, Poblador-Plou B, Lassalle R, Jove J, et al.
Eur J Clin Pharmacol . 2024 Feb; 80(5):707-716. PMID: 38347228
Purpose: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19,...
5.
Blin P, Joubert M, Jourdain P, Zaoui P, Guiard E, Sakr D, et al.
Cardiovasc Diabetol . 2024 Jan; 23(1):22. PMID: 38195491
Background: Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes. The objective...
6.
Baulain R, Jove J, Sakr D, Gross-Goupil M, Rouyer M, Puel M, et al.
Cancer Innov . 2023 Dec; 2(1):52-64. PMID: 38090372
Background: Healthcare pathways of patients with prostate cancer are heterogeneous and complex to apprehend using traditional descriptive statistics. Clustering and visualization methods can enhance their characterization. Methods: Patients with prostate...
7.
Daveluy A, Bryan M, Miremont-Salame G, Lassalle R, Lacueille C, Grelaud A, et al.
Fundam Clin Pharmacol . 2023 Oct; 38(2):389-397. PMID: 37864449
Background: The combination dextropropoxyphene/paracetamol (DXP/P) was the most prescribed opioid analgesic until its withdrawal in 2011. Objectives: This study investigated dispensations of analgesics in chronic users of DXP/P during the...
8.
Bosco-Levy P, Briot K, Mehsen-Cetre N, OKelly J, Desamericq G, Abouelfath A, et al.
JBMR Plus . 2023 Sep; 7(9):e10789. PMID: 37701145
Although drugs for osteoporosis have been demonstrated to be effective in reducing fracture risk in placebo-controlled clinical trials, data on effectiveness in real-world practice is limited. Data from the French...
9.
Bosco-Levy P, Boutmy E, Guiard E, Foch C, Lassalle R, Favary C, et al.
Pharmacoepidemiol Drug Saf . 2023 Aug; 32(12):1421-1430. PMID: 37555380
Purpose: The objective was to compare the risk of malignancies in real-world settings between exclusive immunosuppressant (IS) and immunomodulator (IM) use in multiple sclerosis (MS). Methods: A nested case-control study...
10.
Tan E, Robinson D, Jodicke A, Mosseveld M, Bodkergaard K, Reyes C, et al.
Osteoporos Int . 2023 Jul; 34(10):1771-1781. PMID: 37436441
Purpose: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. Methods: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs)...